The specialty control plasma market is estimated to secure a valuation of US$ 9.8 Billion in 2023 and is estimated to rise to US$ 17.8 Billion by 2033. The market is anticipated at a CAGR of 6.2% during the forecast period. The factors accelerating the demand for specialty control plasma are as follows-
The increasing prevalence of rare and chronic disorders creates more lucrative opportunities for market manufacturers to increase their specialty control plasma share. The increased advancement in plasma-derived products is also expected to drive market growth during the forecast period.
Increased application of products in the treatment of neurological disorders, hemophilia, and increased immunodeficiency disease prevalence is the key driver of the specialty control plasma market globally. Also, the increased demand for high-quality and highly purified plasma in many medical application drive market growths.
North American region is estimated to have a significant specialty control plasma market share owing to its increased development and manufacturing of specialty control plasma in the region. Also, the presence of major players in countries like the USA and Canada provides an opportunity for market growth.
Europe is expected to provide a lucrative opportunity for specialty control plasma market growth during the forecast period due to the increased prevalence of chronic disorders and increased rate of rare diseases in the region.
Asia Pacific is expected to account for a significant share of the specialty control plasma market due to the increasing advances in medical technology and increased prevalence of chronic disorders in the region. Also the growing demand for plasma-delivered therapies and increased awareness about plasma donation drive the specialty control plasma market in the region.
Some of the players operating specialty control plasma are Precision BioLogic Incorporated, Baxter Bioscience, grifols S.A., Shire plc, VitroPharma, Kedrion S.p.A., China Biologic Products, Biotest AG, Sanquin, Telecris Biotherapeutics, SK Plasma Co, CLS Ltd, Octapharma AG, Cerus Corp. among others.
The major players in the specialty control plasma market are using different strategies like mergers, acquisitions, and partnerships to increase their brand presence. Also, the leading players are focusing on innovation to develop innovative specialty control plasma. Some of the developments from the market are listed below.
For instance, in October 2022-To meet the increasing global demand for plasma medicines Grifols started its new state of art manufacturing capacity in Ireland This new plant is part of the company,s growing growth and investment in plasma infrastructure.
The demand for specialty control plasma is expected to flourish during the forecast period owing to rising demand for blood & blood products and increasing incidences of chronic diseases. Also, the advances in technology and growing investments in healthcare boost the growth of the specialty control plasma market. Start-ups are entering the specialty control plasma market with innovative products to fulfill the increased demand for the product.
For instance, founded in 2003- Hemarus is an Indian startup in pharma manufacturing, that develops plasma-derived biopharmaceuticals for bleeding disorders. Their products include coagulation factors, human albumin, immunoglobulins, fibrin sealant, etc. Their plant can process 130,000 liters of plasma annually.
| Data Point | Key statistics |
|---|---|
| Expected Market Value in 2023 | US$ 9.8 Billion |
| Projected Market Value in 2033 | US$ 17.8 Billion |
| Growth Rate (2023 to 2033) | CAGR of 6.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to the latest research by FMI, Specialty Control Plasma is set to witness a 10.6% growth during the year 2021-2031. The specialty control plasma has gained significant traction by its application in the treatment of a range of conditions such as cardiac insufficiency, immune deficiency, hemorrhages, neurological conditions, and infectious diseases. Additionally, specialty control plasma is used by clinical labs for assays to diagnose coagulation disorders such as hemophilia.
The advancement in the process of blood therapeutics and the key application of specialty control plasma in rheumatology, neurology, oncology, immunology, hematology and transplant has proven to be vital in patient care.
The specialty control plasma demand is driven by the rising instances of need of diagnostics for various coagulation disorders. The rising incidence of various autoimmune disorders, such as hemophilia and the growing role of the plasma and its derivative products in the diagnosis as well as treatment of the disorders has significantly acted as a catalyst to the specialty control plasma demand.
In addition, the growing awareness about specialized plasma products and their uptake, especially in the developed economies has added traction to the demand of specialty control plasma. Furthermore, special insurance aid policies by various bodies like the National Hemophilia Foundation, is expected to aid in the development of specialty control plasma.
Principal Consultant
Factors likely to augment the growth of specialty control plasma are the advancements in the specialized plasma-derived products and the plasma fractionation process. The rising geriatric population around the world and the prevalence of infectious diseases is also likely to act as a propelling factor for the specialty control plasma adoption for treatment and patient care.
Apart from this, the rising reported misdiagnosed conditions such as coagulation disorders is set to push the uptake of specialty control plasma for a significantly accurate diagnosis or detection. The advancements in biomedical technologies and detection assays as well as the growing awareness in terms of detection of immunological disorders is set to supplement the growth of specialty control plasma.
The specialty control plasma value is expected to experience profitable growth in the region of North America over the forecast period. The current stance of this region is dominating globally in terms of the development and manufacture of specialty control plasma.
The largest player in USA and Canada, Precision Biologics, recently launched CRYOcheck for the diagnosis of hemophilia A. Therefore, the growth of specialty control plasma in the region of North America is fueled by the rise in expenditure by various biotechnology companies as well as the rising rate of improved healthcare structure.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Europe specialty control plasma market is set to become the most lucrative segment over the forecast period owing to the high incidence of chronic diseases and the recognition and visibility of rare diseases as defined by the European Commission.
About 5000 - 8000 rare diseases are prevalent and affect almost 6-8% of the European population. The increasing fund allocation for such rare disorders has led to the advancement of specialty control plasma techniques for diagnosis as well as treatment or management of such disorders.
The key companies dealing with specialty control plasma are
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Explore Healthcare Insights
View Reports
Specialty Control Plasma Market
